Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Gemeinschaftspraxis Dr. Pourfard & Dr. Uleer

Verified siteinfo

Germany Bahnhofsplatz , 5, 31134 Hildesheim, Germany

  • 2 trials recruiting
  • Breast cancer · Fallopian tube cancer · HER2 positive breast cancer
  • Adult patients

About Specializations

Gemeinschaftspraxis Dr. Pourfard & Dr. Uleer in Hildesheim, Germany specialises in clinical trials of conditions such as Breast cancer, Fallopian tube cancer, HER2 positive breast cancer, Hormone receptor positive HER2 negative breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Breast Cancer Research

The medical center is at the forefront of breast cancer research, focusing on innovative treatments for patients with specific genetic mutations. The center's work is particularly concentrated on germline BRCA mutated high-risk HER2-negative primary breast cancer.

  • Adjuvant Treatment Strategies
  • Genetic Mutation Targeting
  • Invasive Disease Free Survival (IDFS) Improvement

Through its pioneering research, the center is contributing to the development of targeted therapies that aim to improve survival rates and quality of life for patients with challenging breast cancer profiles.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Bahnhofsplatz , 531134 HildesheimGermany
Open in maps ↗
Recruiting now
2 trials
Conditions studied
7
Partner status
Verified site

More sites in HildesheimGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

4 clinical trials

Malignant peritoneal neoplasm+2

Recruiting

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AGO Research GmbH

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Hormone receptor positive breast cancer+1

Not recruiting

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.